352 results
8-K
EX-99.1
LCTX
Lineage Cell Therapeutics, Inc.
8 Aug 24
Lineage Cell Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
4:10pm
, an oligodendrocyte progenitor cell therapy in Phase 1/2a development for the treatment of spinal cord injuries; (iii) ANP1, an auditory neuronal progenitor cell
424B5
LCTX
Lineage Cell Therapeutics, Inc.
14 May 24
Prospectus supplement for primary offering
4:36pm
the safety and utility of a novel spinal cord delivery device in both subacute and chronic spinal cord injuries and continues to be evaluated in long-term … follow-up from a Phase 1/2a multicenter clinical trial for subacute cervical spinal cord injuries.
ANP1, an allogeneic auditory neuron progenitor cell
8-K
EX-99.1
LCTX
Lineage Cell Therapeutics, Inc.
9 May 24
Lineage Cell Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
4:10pm
, an oligodendrocyte progenitor cell therapy in Phase 1/2a development for the treatment of spinal cord injuries; (iii) ANP1, an auditory neuronal
424B5
c8zfvv0 cin0
22 Mar 24
Prospectus supplement for primary offering
4:32pm
8-K
EX-99.1
s6d9a12 4jyro
7 Mar 24
Lineage Cell Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
4:10pm
424B5
wbjspif80hi
6 Feb 24
Prospectus supplement for primary offering
9:25am
8-K
EX-99.1
bjn7u7ub3kumdjl6406o
6 Feb 24
Lineage Cell Therapeutics Announces $14.0 Million Registered Direct Offering
9:20am
8-K
EX-99.1
6t21bhimq2iy vg
9 Nov 23
Lineage Cell Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update
4:10pm
8-K
EX-99.1
twpnb8imlkryrt
10 Aug 23
LINEAGE CELL THERAPEUTICS REPORTs SECOND QUARTER 2023 FINANCIAL
4:10pm
8-K
EX-99.1
gn505 mergo6fol
11 May 23
LINEAGE CELL THERAPEUTICS REPORTs FIRST QUARTER 2023 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE
4:10pm
8-K
EX-99.1
ovlhmib0a uxf
10 Nov 22
LINEAGE CELL THERAPEUTICS REPORTs THIRD QUARTER 2022 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE
4:11pm